Phase analysis data and within group correlations. by Aaron L. Sayler (19797446)

Subjects:

Effect of <i>slc43a3</i> deletion on the diurnal cycle of oxygen consumption (VO₂) in male and female mice. by Aaron L. Sayler (19797446)

Subjects:

S1 Graphical abstract - by Aman Goyal (19231397)

Subjects:

Paroxysmal tachycardia-related age-adjusted mortality rates per 100,000, stratified by census regions in adults in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

Pathophysiological mechanisms linking hyperammonemia to sarcopenia and cerebral changes. by Maria Nadinskaia (22662419)

Subjects:

Effect of <i>slc43a3</i> deletion on physical activity of male and female WT and KO mice. by Aaron L. Sayler (19797446)

Subjects:

Paroxysmal tachycardia-related age-adjusted mortality rates per 100,000 in adults in the metropolitan and non-metropolitan areas in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

Supporting information – data for plots. by Maria Nadinskaia (22662419)

Subjects:

Summary of measured parameters. by Aaron L. Sayler (19797446)

Subjects:

Morphometric analysis of histological slides in sarcopenia modeling by portal vein ligation and pyloric vein ligation. by Maria Nadinskaia (22662419)

Subjects:

Effect of <i>slc43a3</i> deletion on metabolic performance parameters in male and female WT and KO mice. by Aaron L. Sayler (19797446)

Subjects:

Raw data. by Aaron L. Sayler (19797446)

Subjects:

Paroxysmal tachycardia-related age-adjusted mortality rates per 100,000, stratified by race in adults in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

Paroxysmal tachycardia-related age-adjusted mortality rates per 100,000, stratified by age groups in adults in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

Liver and spleen mass in sarcopenia-hyperammonemia modelling on Day 30. by Maria Nadinskaia (22662419)

Subjects:

Paroxysmal tachycardia-related deaths and age-adjusted mortality rates per 100,000, stratified by state in adults in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

Effect of ibuprofen (IBU) on COX-2 expression. by Katarina Grossmannova (7543517)

“…In FaDu cells, only the ERK1/2 inhibitor decreased the level of IBU-mediated COX-2 expression.…”

Time series comparing trends at HSJ and control hospitals in the pre-intervention and intervention period. Significance test determine if trends differ between groups. by Eva Rydahl (6260771)

Subjects:

Effect of ibuprofen (IBU) on carbonic anhydrase IX (CA IX) expression. by Katarina Grossmannova (7543517)

“…P < 0.05 was considered significant. * denotes P < 0.05, **P < 0.01, *** P < 0.001, and **** P < 0.0001, respectively. …”

STM2457 and PD98059 enhanced PRV replication <i>in vivo.</i> by Lucai Wang (22050158)